News

SPARX3, an ongoing clinical trial investigating the effects of moderate– and high-intensity aerobic exercise — specifically, treadmill walking four times per week — in Parkinson’s disease, is still recruiting patients at 23 sites in the U.S. and one in Canada, according to the…

A new treatment that delivers healthy mitochondria to damaged nerve cells showed promise in cell and animal models of Parkinson’s disease, a study shows. “[T]he study findings provide evidence that mitochondria transplantation can be developed as a novel therapeutic for” Parkinson’s, researchers wrote in “Mitochondrial transplantation…

A new machine learning model is able to identify Parkinson’s disease more accurately than other models based on electroencephalography (EEG) readings of the brain’s electrical activity, a study found. “The proposed model holds promising potential as a valuable and enduring aid for experts and clinicians in diagnosing” Parkinson’s, researchers…

Rumble Boxing, a U.S. fitness brand, is partnering for the second year with Team Fox, the grassroots fundraising community of The Michael J. Fox Foundation (MJFF), to raise awareness and funds during Parkinson’s Disease Awareness Month this April. Among Rumble’s planned activities is a multicity tour panel…

The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for Parkinson’s disease linked to mutations in the GBA gene, the company has announced. The Phase 1 clinical trial is assessing the safety, tolerability, and pharmacological properties of VQ-101 in both…

A widening of tiny, fluid-filled spaces in certain brain regions could be used as an imaging marker of levodopa-induced dyskinesia (LID) in people with Parkinson’s disease, a study showed. Perivascular spaces, or PVSs, were larger in Parkinson’s patients with LID — a condition in which standard Parkinson’s medications…

NeuroVigil has launched its iBrain personal brain monitor — an investigational portable device that can noninvasively record the brain’s electrical activity in people with neurological conditions — in the U.S., according to a company press release. In the second phase of the launch, NeuroVigil will use a smaller…

The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…

DrTalks, a platform that aims to advance wellness and medicine by connecting people with health experts, has set the dates for its virtual meeting in November — dubbed the Parkinson’s Solutions Summit 2.0 — designed to provide insights into how to better manage and treat the progressive neurodegenerative…

Levels of two markers of intestinal inflammation — beta-defensin 2 and lactoferrin — were elevated in the stools of Parkinson’s disease patients when compared with healthy adults, and were associated with a likelihood of developing the disease, a study found. Calprotectin, a marker of tissue inflammation, wasn’t found to…